Verra Mobility Corporation (VRRM) shares fell approximately 16.05% from the prior session close of $4.89 to the latest available price near $4.105. The decline followed reports of multiple securities fraud investigations targeting the company and its investors.
VLGEA shares plunged more than 19% following the release of fiscal third-quarter results. Primary catalyst was the company's earnings report showing modest sales growth but pressure on margins and profitability metrics.
Virgin Galactic Holdings, Inc. (SPCE) shares plunged 36.77% intraday as the stock traded near $4.76 after closing the prior session at $7.52.
ABVX shares fell sharply, declining approximately 44.56% from the prior session's close of $129.69. The primary catalyst was a cancer signal identified in the ABTECT Phase 3 trial for obefazimod in ulcerative colitis, overshadowing positive efficacy results.
PRAX shares are down approximately 9% in premarket trading on June 2, 2026, from the prior session close of $335.16 to an implied level near $304.99. The primary catalyst is the after-hours announcement on June 1 that the Phase 2/3 POWER1 clinical trial evaluating vormatrigine in adults with focal onset seizures failed to meet its primary endpoint — the percent change in monthly seizure frequency from baseline.
FULC shares are collapsing approximately 51% in premarket trading on June 2, 2026, from a prior close of $6.42 to a premarket price near $3.16. The sole and decisive catalyst is the company's announcement that it is permanently discontinuing its lead drug candidate, pociredir, for sickle cell disease after the FDA concluded there is no viable regulatory path forward due to malignancy risk concerns tied to the drug's mechanism of action.
Boeing reported Q1 2026 revenue of $22.2 billion with a narrower-than-expected loss, supported by 143 commercial deliveries. The company secured multiple defense contracts worth hundreds of millions, including awards from the Air Force, Navy, and Defense Logistics Agency.
Northrop Grumman reported Q1 2026 results that beat revenue and earnings estimates but triggered a notable stock decline due to elevated cash usage and a segment-specific adjustment. The company raised its quarterly dividend by approximately 7% to $2.47 per share in May 2026, underscoring commitment to shareholder returns.
Lockheed Martin secured multiple major U. S.
Lockheed Martin secured multiple major U. S.
Trimble Inc. reported first-quarter 2026 results that exceeded analyst expectations, driven by recurring revenue growth and software momentum.
Joby Aviation reported first-quarter 2026 revenue of $24.2 million, exceeding estimates, alongside a net loss of $110 million that improved sequentially. The company strengthened its balance sheet to approximately $2.5 billion in cash, cash equivalents, and short-term investments through equity and convertible note offerings.
Archer Aviation advanced key FAA certification phases for its Midnight aircraft, positioning the company closer to initial U. S.
Amazon delivered robust first-quarter results with strong AWS growth, setting a positive tone for recent trading. Upcoming Prime Day event from June 23-26 highlights retail strength and customer engagement strategies.
ODD shares are falling approximately 20% in premarket trading on June 2, 2026, from a prior session close of $13.98, implying a premarket price near $11.18. The primary catalyst is the Q1 2026 earnings report released before the open, showing net revenue of $197.9 million — a steep 26% year-over-year decline from $268.1 million in Q1 2025.
Swarmer, Inc. completed its Nasdaq IPO in March 2026, raising $17.3 million to support growth in drone autonomy software.
CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42. The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction.
Veeva Systems is scheduled to report fiscal 2027 first-quarter results on June 3, 2026. The company provided revenue guidance of $855 million to $858 million for the quarter.
Medtronic is set to report fourth-quarter and full fiscal year 2026 results on June 3, 2026. Analyst consensus estimates call for Q4 revenue near $9.62 billion and non-GAAP EPS of approximately $1.55.